CAJ | 학술논문

目的评价比阿培南治疗恶性血液病患者合并中、重度感染时的临床疗效及安全性.方法回顾性分析2011年1月至2012年6月在我科住院的134例恶性血液病患者合并感染后应用比阿培南治疗的疗效.比阿培南用药剂量为0.3g每8小时1次静脉滴注,疗程3～24d.按卫生部颁发的抗菌药物临床研究指导原则判定疗效.结果比阿培南治疗本组恶性血液病合并感染的有效率为78.4％(105/134,痊愈+显效);在合并败血症19例中,16例有效;中性粒细胞绝对数在0.5×109/L以下者,有效率达73.5％ (61/83).不良反应发生率为3.7％ (4/134).结论比阿培南治疗恶性血液病合并感染疗效显著,安全性好.
목적 평개비아배남치료악성혈액병환자합병중、중도감염시적림상료효급안전성.방법 회고성분석2011년1월지2012년6월재아과주원적134례악성혈액병환자합병감염후응용비아배남치료적료효.비아배남용약제량위0.3g매8소시1차정맥적주,료정3～24d.안위생부반발적항균약물림상연구지도원칙판정료효.결과 비아배남치료본조악성혈액병합병감염적유효솔위78.4％(105/134,전유+현효);재합병패혈증19례중,16례유효;중성립세포절대수재0.5×109/L이하자,유효솔체73.5％ (61/83).불량반응발생솔위3.7％ (4/134).결론 비아배남치료악성혈액병합병감염료효현저,안전성호.
Objective To investigate the clinical efficacy and tolerance of intravenous biapenem treating infections in 134 patients with hematologic malignancy.Methods The clinical data of 134 cases of biapenemtreated infections in patients with hematologic malignancy were reviewed in department of hematology from January 2011 to June 2012.The dosage of biapenem was 0.3 g q8h for all infections.The treatment duration was 3 to 24 days.The efficacy evaluation was conducted according to the guidelines on clinical trial of antimicrobial agents released by ministry of health.Results Biapenem treatment was effective in 78.4％ (105/134) of patients with hematologic malignancy.Biapenem was also effective in 16/19 cases of septicemia.Biapenem was effective in 73.5％ (61/83) of patients whose absolute neutrophils count was lower than 0.5 × 109/L.The incidence of adverse reactions was 3.7％ (4/134).Conclusions Biapenem is high effective and tolerant in treating infections of patients with hematologic malignancy.